quarta-feira, 7 de outubro de 2026
PesquisarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· January 5, 2026

Beat the Market the Zacks Way: LATAM, General Motors, Amgen in Focus

View original at finance.yahoo.com
Beat the Market the Zacks Way: LATAM, General Motors, Amgen in Focus Last Friday, the three most widely followed benchmark indexes closed a losing week…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The Zacks Earnings Certain Dividend Portfolio (ECDP) returned -0.01% in 2025 Q3 vs. the S&P 500 index's +8.1% gain and the Dividend Aristocrats ETF's (NOBL) +2.90% return

    80% confidence
  • Year-to-date (through September 30th), the ECDP portfolio returned +1.58% vs. +5.15% gain for the Dividend Aristocrat ETF

    80% confidence
  • The Zacks Focus List portfolio returned +18.41% in 2024 vs. +25.04% for the S&P 500 index and +13% for the equal-weight S&P 500 index

    80% confidence
  • The Zacks Focus List portfolio returned +29.54% in 2023 vs. +26.28% for the S&P 500 index and +13.61% for the equal-weight S&P 500 index

    80% confidence
  • For the full year 2024, the ECDP portfolio returned +6.95% vs. +24.89% for the S&P 500 index and +6.72% for NOBL

    80% confidence
  • The Top 10 portfolio returned +25.4% in 2025 (through the end of November) vs. +17.8% for the S&P 500 index and +10.9% for the equal-weight version of the index

    80% confidence
  • The ECDP portfolio returned -0.9% in 2023 vs. +26.28% for the S&P 500 index and +8.11% for NOBL

    80% confidence
  • The ECAP portfolio returned -4.7% in 2022 vs. the S&P 500 index's -17.96%

    80% confidence
  • Year-to-date through September 30th, the ECAP portfolio returned +2.72% vs. +14.84% gain for the S&P 500 index

    80% confidence
  • The ECDP portfolio returned -2.3% in 2022 vs. -17.96% for the S&P 500 index and -8.34% for NOBL

    80% confidence
  • The Top 10 portfolio returned +62.98% in 2024, vs. +25.04% for the S&P 500 index and +13% for the equal-weight version of the index

    80% confidence
  • In 2022, the Zacks Focus List portfolio returned -15.2% vs. the S&P 500 index's -17.96%

    80% confidence
  • The 50-stock Focus List portfolio returned +22% in 2025 (through November 30th, 2025) vs. +17.8% for the S&P 500 index and +10.9% for the equal-weight version of the index

    80% confidence
  • The Top 10 portfolio has produced an average return of +26.1% in the period 2012 through November 30, 2025, vs. +13.2% for the S&P 500 index and +10.5% for the equal-weight version of the index

    80% confidence
  • Hypothetical portfolio of Zacks Rank #1 stocks returned +22.4% in 2024, vs. +28% for the S&P 500 index and +19.9% for the equal-weight version of the S&P 500 index

    80% confidence
  • Hypothetical portfolio returned +20.65% in 2023 vs. +24.83% for the S&P 500 index and +15% for the equal-weight S&P 500 index

    80% confidence
  • The Zacks Earnings Certain Admiral Portfolio (ECAP) returned -1.30% in the third quarter of 2025 vs. the S&P 500 index's +8.1% gain

    80% confidence
  • In 2023, the ECAP portfolio returned +12.17% vs. +26.28% for the S&P 500 index

    80% confidence
  • The Zacks Model Portfolio consisting of Zacks Rank #1 stocks has outperformed the S&P index by more than 12 percentage points since 1988, generating an annualized average return of +23.9% vs. +11.5% for the S&P 500 index through December 1st, 2025

    80% confidence
  • A hypothetical portfolio of Zacks Rank #1 (Strong Buy) stocks returned +14.3% in 2025 (through December 1st) vs. +14.9% for the S&P 500 index

    80% confidence
  • Since 2012, the Top 10 portfolio has produced a cumulative return of +2,530.8% through the end of November 2025 vs. +562% for the S&P 500 index and +401% for the equal-weight version of the index

    80% confidence
  • For the year 2024, the ECAP portfolio returned +16.26% vs. +24.89% for the S&P 500 index

    80% confidence
  • The Top 10 portfolio returned +25.15% in 2023 vs. +26.28% for the S&P 500 index

    80% confidence
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
A nossa leitura dos dados ›
Sinais que acompanhamos
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Padrões que observamos ›
Onde as fontes divergem
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,986
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,986 factos verificados com a fonte5,351 documentos-fonte arquivados
Consulte estes dados → isubstrate.com